CVM
What one share of Cel-Sci holds
Biological Products, (No Diagnostic Substances)
CEL-SCI Corporation is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body’s natural defense system.
Cel-Sci’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$2.57 |
|---|---|
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$1.90 |
| Cash and investments | $0.37 |
| Debt | $0.45 |
| Book value | $0.62 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | — | −$70.97 | $0.19 | −$142.50 | — | — |
| 2017 | — | −$57.34 | $0.04 | −$52.40 | — | — |
| 2018 | — | −$56.17 | $0.00 | −$23.62 | — | — |
| 2019 | — | −$21.30 | −$0.17 | −$15.53 | — | $4.37 |
| 2020 | — | −$24.69 | $2.17 | −$14.63 | — | $15.28 |
| 2021 | — | −$27.06 | $6.65 | −$20.50 | — | $39.25 |
| 2022 | — | −$26.16 | $0.44 | −$13.13 | — | $22.21 |
| 2023 | — | −$21.83 | $0.24 | −$15.65 | — | $8.36 |
| 2024 | — | −$15.31 | $0.05 | −$10.49 | — | $6.05 |
| 2025 | — | −$6.27 | $0.01 | −$4.23 | — | $1.99 |